Acuson’s first-quarter earnings down

Article

Ultrasound manufacturer Acuson said its first-quarter (end April 31) 2000 revenue was down approximately $8 million compared to the first quarter of 1999. First-quarter 2000 revenue was $111.6 million, compared to $119 million in first quarter

Ultrasound manufacturer Acuson said its first-quarter (end April 31) 2000 revenue was down approximately $8 million compared to the first quarter of 1999. First-quarter 2000 revenue was $111.6 million, compared to $119 million in first quarter 1999.

Earnings per share for the quarter were 7¢ compared to 21¢ for the same period a year earlier.

Acuson announced estimates of these earnings last month. The final results fell within Acuson’s expected range of $110 million to $112 million.

“As we reported last week, orders for our base ultrasound platform business met our expectations and increased strongly over the first quarter of last year,” said Samuel H. Maslak, Acuson’s CEO and chairman of the board, in a statement. “However, later-than-expected receipt of these orders precluded us from achieving our revenue target for the quarter.”

Maslak also blamed the low earnings on lower-than-expected revenue for the KinetDx Ultrasound PACS solution.

At the end of the first quarter of this year, Acuson had $27.1 million in cash. At the end of the fourth quarter of 1999, the company had $23.7 million in cash (not $157 million as reported in SCAN 4/26/00). Acuson had $144 million in accounts receivable at the end of first-quarter 2000.

Despite the slow quarter, the company said orders for its Cypress platform were very strong. The Cypress system marks Acuson’s entry into the low- to mid-range cardiology ultrasound market.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.